Johnson & Johnson/Theravance ulcerative colitis drug idencitinib failed Phase II clinical trial

CompilationFan Dongdong

Ulcerative colitis drug idencitinib is the main project of the cooperation between Theravance and Johnson & Johnson subsidiary Xi'an Janssen

In 2018, Xi'an Janssen paid Theravance US$100 million in advance to start the partnership between the two companies and promised to pay an additional US$900 million for potential milestone payments

Previously, other JAK inhibitors on the market have entered the market for autoinflammatory diseases (such as rheumatoid arthritis), and Theravance has focused the development of idencitinib on gastrointestinal diseases, with inflammatory bowel disease and ulcerative colon.

A total of 239 patients were recruited in the Phase 2 trial.

Although the efficacy results of all dose groups were disastrous, Theravance said that patients who received the three doses of idencitinib showed good tolerability, and the incidence of adverse events in the treatment group and the placebo group was similar

More than 5 million people worldwide suffer from inflammatory bowel disease, mainly including ulcerative colitis and Crohn’s disease.

In view of the fact that the data for ulcerative colitis is not as expected, Theravance said it will minimize future R&D expenditures on idencitinib

Reference source:

1.

2.